FHN vs IVZ

FHN presents a stark contrast between attractive valuation and deteriorating fundamental health, highlighted by a weak Piotroski F-Score of 2/9. While the current price of $24.21 is a discount to both the Graham Number ($28.16) and the growth-based Intrinsic Value ($58.7), the low health score and bearish insider activity suggest significant underlying risks. These concerns are partially offset by strong earnings growth (29.3% YoY) and a consistent track record of beating analyst estimates. Consequently, the stock is a high-risk value play where growth metrics clash with poor deterministic health indicators.

Invesco Ltd. presents a stark contrast between deep value metrics and deteriorating fundamental health, highlighted by a weak Piotroski F-Score of 2/9. While the valuation is highly attractive with a Forward P/E of 8.84 and a PEG ratio of 0.38, the company struggles with a negative profit margin (-4.42%) and a current ratio below 1.0 (0.79), indicating liquidity pressures. Despite a massive 93% one-year price increase, the current technical trend is heavily bearish (10/100). The investment case rests on whether the low valuation provides enough margin of safety to offset the poor financial health scores.